Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further ...

Cash burn is likely to moderate going forward, as investments in Schrödinger's internal pipeline have now stabilized. Read ...

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...

IPWatchdog LIVE opened today with a sneak preview of the latest episode of the IPWatchdog Unleashed podcast, where IPWatchdog ...

Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.